Fifth Circuit reinstates nationwide in-person dispensing requirement for mifepristone, blocking telehealth and mail access

On May 1, 2026, the Fifth Circuit Court of Appeals issued its ruling in Louisiana v. FDA, ordering the FDA to temporarily reimpose in-person dispensing requirements on mifepristone that the agency had permanently removed in 2023 based on robust clinical evidence. The ruling is nationwide in scope: it does not merely apply to Louisiana patients, but eliminates telehealth prescribing and mail dispensing of mifepristone everywhere in the country while the appeal proceeds. The court prioritized Louisiana's assertion that the FDA's 2023 REMS cancels Louisiana's ban on medical abortions and undermines its policy over decades of FDA safety findings and the lower court's considered balancing of the equities — a breathtaking subordination of federal pharmaceutical authority to a single state's abortion ban. The Trump administration's own FDA had already handed the court its standing argument by launching a safety review, and, as the ACLU documented, DOJ's brief never once defended the merits of the FDA's evidence-based decision to allow mail and pharmacy dispensing.

The human cost is immediate and vast. Medication abortion accounts for roughly two out of every three abortions nationwide, according to Guttmacher Institute. The Society of Family Planning's #WeCount data shows that 27 percent of all abortions within the U.S. healthcare system were provided via telehealth in the first half of 2025, up from 5 percent in Q2 2022 — a post-Dobbs care infrastructure that patients in restrictive states built out of necessity. By June 2025, the most recent #WeCount report found that 55 percent of all telehealth abortions were provided under shield laws, with nearly 15,000 such abortions per month — a share that had grown from 49 percent of all telehealth abortions for full-year 2024, reflecting rapid acceleration precisely as other access routes closed. Every one of those pathways is now severed for the duration of this litigation. Disabled patients face compounded harm: people with disabilities face an approximately eleven-times greater risk of dying in childbirth than non-disabled people, and for many, quick and private access to mifepristone was the difference between safety and catastrophic, irreversible harm — yet the Fifth Circuit's opinion said nothing about the ADA, Section 504, or Congress's explicit prohibition on FDA rules that create unnecessary burdens on patients with functional limitations.

The civil-rights frame is essential here. EMTALA, the ADA, Section 504, and the federal preemption doctrine all supply DOJ with tools to push back against state efforts to nullify federal pharmaceutical safety determinations — but only if DOJ chooses to use them. A Civil Rights Division fully staffed and directed to defend reproductive rights would be filing amicus briefs, asserting federal preemption arguments, and coordinating with mifepristone manufacturers who have already sought emergency Supreme Court relief. Instead, DOJ offered no defense of the 2023 REMS on the merits, and the Trump FDA's own ongoing safety review — prompted, as the ACLU documented, by a self-published, non-peer-reviewed paper from a Project 2025 sponsor — supplied Louisiana with the standing hook the Fifth Circuit needed.

The path forward requires the Supreme Court to grant emergency relief to restore telehealth access while full merits briefing proceeds — relief that mifepristone manufacturers Danco and GenBioPro sought the very next day. It also requires Congress to codify the 2023 REMS changes into statute so that no single circuit can override evidence-based FDA rulemaking by crediting a state's interest in enforcing an abortion ban as irreparable harm. Longer term, the Civil Rights Division must be resourced and directed to treat reproductive-rights legal defense — grounded in EMTALA, the ADA, and federal preemption — as a standing enforcement priority, not an afterthought.